Samsung Bioepis, Teva Expand Biosimilar Partnership to Six Candidates
Samsung Bioepis and Teva Pharmaceutical Industries have expanded their global license, development, and commercialization agreement to include up to six potential biosimilar candidates, two of which are confirmed investigational biosimilars.
Story updates
08:30:39 AM UTC
SquawkNews
Teva and Samsung Bioepis entered a global license, development and commercialization agreement for up to six biosimilar candidates, with SB41 (Fasenra reference) and SB44 (Ilaris reference) confirmed. Samsung Bioepis will develop and manufacture; Teva will commercialize in key markets.Material Deta…